These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31704599)

  • 1. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.
    Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE
    Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
    Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
    Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
    Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
    Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
    Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification.
    Ungan G; Lavandier AF; Rouanet J; Hordonneau C; Chauveau B; Pereira B; Boyer L; Garcier JM; Mansard S; Bartoli A; Magnin B
    Int J Comput Assist Radiol Surg; 2022 Oct; 17(10):1867-1877. PubMed ID: 35650345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
    Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
    Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
    Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
    [No Abstract]   [Full Text] [Related]  

  • 11. Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
    Almansour H; Afat S; Serna-Higuita LM; Amaral T; Schraag A; Peisen F; Brendlin A; Seith F; Klumpp B; Eigentler TK; Othman AE
    Acad Radiol; 2022 Apr; 29(4):514-522. PubMed ID: 34130924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
    Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
    Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
    Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
    Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
    PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma.
    Brendlin AS; Peisen F; Almansour H; Afat S; Eigentler T; Amaral T; Faby S; Calvarons AF; Nikolaou K; Othman AE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters.
    Mohseni A; Baghdadi A; Madani SP; Shahbazian H; Mirza-Aghazadeh-Attari M; Borhani A; Afyouni S; Zandieh G; Baretti M; Kim AK; Yarchoan M; Kamel IR
    Abdom Radiol (NY); 2024 Aug; 49(8):2595-2605. PubMed ID: 38546828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.